Pharmacotherapy of acute and chronic heart failure: Part 1

Lindenfeld, JoAnn

doi:10.1007/s11897-009-0001-0

Cited by 1 publication

(1 citation statement)

References 7 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Drawing from clinical experience with trastuzumab and sunitinib, patients with TKI-induced cardiac dysfunction generally respond well to standard heart failure management for nonischemic cardiomyopathy, as outlined by the American Heart Association (AHA)/American College of Cardiology (ACC) and the Heart Failure Society of America [3••,10••,15•,18,45••, [46][47][48]. Pretreatment cardiac assessment of high-risk patients may be prudent to minimize cardiotoxicity and avoid interruption of long-term anticancer therapy.…”

Section: Treatment Of Heart Failure and Cardiomyopathy Induced By Tarmentioning

confidence: 99%

Cardiac dysfunction induced by novel targeted anticancer therapy: An emerging issue

Chen

2009

Curr Cardiol Rep

View full text Add to dashboard Cite

Increasing use of targeted anticancer agents that inhibit tyrosine kinase signaling (monoclonal antibodies or tyrosine kinase inhibitors) has dramatically improved the survival of patients with malignancies. However, cardiotoxicity, including heart failure, left ventricular dysfunction, hypertension, myocardial infarction, and thromboembolism, has occurred. Importantly, these cardiotoxicities are at least partially reversible and responsive to medical management. Early recognition of cardiovascular side effects is vital to allow long-term, continuous therapy with these life-prolonging agents. This article reviews potential cardiovascular side effects of frequently used inhibitors of tyrosine kinase activity (eg, trastuzumab, sunitinib) and discusses the diagnosis and management of cardiotoxicity associated with targeted therapy.

show abstract

Section: Treatment Of Heart Failure and Cardiomyopathy Induced By Tarmentioning

confidence: 99%

Cardiac dysfunction induced by novel targeted anticancer therapy: An emerging issue

Chen

2009

Curr Cardiol Rep

View full text Add to dashboard Cite

show abstract

Pharmacotherapy of acute and chronic heart failure: Part 1

Cited by 1 publication

References 7 publications

Cardiac dysfunction induced by novel targeted anticancer therapy: An emerging issue

Cardiac dysfunction induced by novel targeted anticancer therapy: An emerging issue

Contact Info

Product

Resources

About